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Application of SELDI-TOF in N-glycopeptides profiling of the urine from patients with 
endometrial, ovarian and cervical cancer 
 
ABSTRACT 
Purpose: Endometrial (ECa), ovarian (OCa) and cervical (CCa) cancers are among 10 of the 
most common cancers affecting women worldwide. Cancers are known to cause some 
proteins to be differentially glycosylated or aberrantly excreted in the urine, which can be 
used as biomarkers. Since ECa, OCa and CCa are difficult to diagnose at the early stage, the 
aim of the present study was to identify a panel of new biomarkers for early detection of the 
cancers using surface-enhanced laser desorption/ionization-time-of-flight (SELDI-TOF) 
technology. Identification of early biomarkers that are specific and efficient can increase the 
survival rate of the patients. Experimental design: Digested urinary proteins from patients 
with ECa, OCa and CCa were incubated on the champedak mannose-binding (CMB) lectin-
immobilized PS10 chip. The lectin-captured glycopeptides were detected with SELDI-TOF 
mass spectrometry and followed by biomarker wizard analysis. Results: Peaks m/z 1201 and 
1449 were detected as potential group discriminators. The peak m/z 1201 could distinguish 
OCa from CCa and ECa and its sensitivity and specificity were 100%. For m/z 1449, it was 
able to differentiate ECa from the other two types of cancer. Conclusions: The findings of 
this study suggest urinary glycopeptides m/z 1201 and 1449 may serve as potential 
biomarkers for the early detection of ECa, OCa and CCa, although this requires further 
extensive validation on clinically representative populations. 
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